Literature DB >> 23409931

Nonstructural protein 2 (nsP2) of Chikungunya virus (CHIKV) enhances protective immunity mediated by a CHIKV envelope protein expressing DNA Vaccine.

Huihui Bao1, Aarti A Ramanathan, Omkar Kawalakar, Senthil G Sundaram, Colleen Tingey, Charoran B Bian, Nagarajan Muruganandam, Paluru Vijayachari, Niranjan Y Sardesai, David B Weiner, Kenneth E Ugen, Karuppiah Muthumani.   

Abstract

Chikungunya virus (CHIKV) is an important emerging mosquito-borne alphavirus, indigenous to tropical Africa and Asia. It can cause epidemic fever and acute illness characterized by fever and arthralgias. The epidemic cycle of this infection is similar to dengue and urban yellow fever viral infections. The generation of an efficient vaccine against CHIKV is necessary to prevent and/or control the disease manifestations of the infection. In this report, we studied immune response against a CHIKV-envelope DNA vaccine (pEnv) and the role of the CHIKV nonstructural gene 2 (nsP2) as an adjuvant for the induction of protective immune responses in a relevant mouse challenge model. When injected with the CHIKV pEnv alone, 70% of the immunized mice survived CHIKV challenge, whereas when co-injected with pEnv+pnsP2, 90% of the mice survived viral challenge. Mice also exhibited a delayed onset signs of illness, and a marked decrease in morbidity, suggesting a nsP2 mediated adjuvant effect. Co-injection of the pnsP2 adjuvant with pEnv also qualitatively and quantitatively increased antigen specific neutralizing antibody responses compared to vaccination with pEnv alone. In sum, these novel data imply that the addition of nsP2 to the pEnv vaccine enhances anti-CHIKV-Env immune responses and maybe useful to include in future CHIKV clinical vaccination strategies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23409931      PMCID: PMC4845693          DOI: 10.1089/vim.2012.0061

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  36 in total

1.  Functional Sindbis virus replicative complexes are formed at the plasma membrane.

Authors:  Elena I Frolova; Rodion Gorchakov; Larisa Pereboeva; Svetlana Atasheva; Ilya Frolov
Journal:  J Virol       Date:  2010-09-08       Impact factor: 5.103

2.  Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling.

Authors:  Jelke J Fros; Wen Jun Liu; Natalie A Prow; Corinne Geertsema; Maarten Ligtenberg; Dana L Vanlandingham; Esther Schnettler; Just M Vlak; Andreas Suhrbier; Alexander A Khromykh; Gorben P Pijlman
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

3.  A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates.

Authors:  Karthik Mallilankaraman; Devon J Shedlock; Huihui Bao; Omkar U Kawalekar; Paolo Fagone; Aarthi A Ramanathan; Bernadette Ferraro; Jennifer Stabenow; Paluru Vijayachari; Senthil G Sundaram; Nagarajan Muruganandam; Gopalsamy Sarangan; Padma Srikanth; Amir S Khan; Mark G Lewis; J Joseph Kim; Niranjan Y Sardesai; Karuppiah Muthumani; David B Weiner
Journal:  PLoS Negl Trop Dis       Date:  2011-01-11

4.  Comparative full genome analysis revealed E1: A226V shift in 2007 Indian Chikungunya virus isolates.

Authors:  S R Santhosh; P K Dash; M M Parida; M Khan; M Tiwari; P V Lakshmana Rao
Journal:  Virus Res       Date:  2008-04-01       Impact factor: 3.303

5.  Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus.

Authors:  Dominick J Laddy; Jian Yan; Amir S Khan; Hanne Andersen; Amanda Cohn; Jack Greenhouse; Mark Lewis; Jody Manischewitz; Lisa R King; Hana Golding; Ruxandra Draghia-Akli; David B Weiner
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

Review 6.  Chikungunya: a potentially emerging epidemic?

Authors:  Michelle M Thiboutot; Senthil Kannan; Omkar U Kawalekar; Devon J Shedlock; Amir S Khan; Gopalsamy Sarangan; Padma Srikanth; David B Weiner; Karuppiah Muthumani
Journal:  PLoS Negl Trop Dis       Date:  2010-04-27

7.  Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine.

Authors:  Krystle A Lang; Jian Yan; Ruxandra Draghia-Akli; Amir Khan; David B Weiner
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

8.  Molecular and serological diagnosis of Chikungunya virus infection.

Authors:  P Grivard; K Le Roux; P Laurent; A Fianu; J Perrau; J Gigan; G Hoarau; N Grondin; F Staikowsky; F Favier; A Michault
Journal:  Pathol Biol (Paris)       Date:  2007-10-24

9.  Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus.

Authors:  Mugdha Tiwari; Manmohan Parida; S R Santhosh; Mohsin Khan; Paban Kumar Dash; P V Lakshmana Rao
Journal:  Vaccine       Date:  2009-02-27       Impact factor: 3.641

10.  Chikungunya fever, Andaman and Nicobar Islands, India.

Authors:  Sathya P Manimunda; Shiv S Singh; Attayoor P Sugunan; Omkar Singh; Subarna Roy; Ananganallur N Shriram; A P Bharadwaj; Wajid A Shah; Paluru Vijayachari
Journal:  Emerg Infect Dis       Date:  2007-08       Impact factor: 6.883

View more
  6 in total

Review 1.  Vaccine and Therapeutic Options To Control Chikungunya Virus.

Authors:  Ann M Powers
Journal:  Clin Microbiol Rev       Date:  2017-12-13       Impact factor: 26.132

Review 2.  Insights into Antibody-Mediated Alphavirus Immunity and Vaccine Development Landscape.

Authors:  Anthony Torres-Ruesta; Rhonda Sin-Ling Chee; Lisa F P Ng
Journal:  Microorganisms       Date:  2021-04-22

3.  Plant expression systems, a budding way to confront chikungunya and Zika in developing countries?

Authors:  Jaime A Cardona-Ospina; Juan C Sepúlveda-Arias; L Mancilla; Luis G Gutierrez-López
Journal:  F1000Res       Date:  2016-08-31

4.  Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.

Authors:  Zhimin Zhao; Yao Deng; Peihua Niu; Jingdong Song; Wen Wang; Yongping Du; Baoying Huang; Wenling Wang; Leiliang Zhang; Ping Zhao; Wenjie Tan
Journal:  Front Immunol       Date:  2021-03-24       Impact factor: 7.561

Review 5.  Chikungunya vaccines in development.

Authors:  Michael Schwameis; Nina Buchtele; Patricia Pia Wadowski; Christian Schoergenhofer; Bernd Jilma
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

Review 6.  Cellular and Molecular Immune Response to Chikungunya Virus Infection.

Authors:  Ithallo S B Tanabe; Eloiza L L Tanabe; Elane C Santos; Wanessa V Martins; Isadora M T C Araújo; Maria C A Cavalcante; Ana R V Lima; Niels O S Câmara; Leticia Anderson; Dinar Yunusov; Ênio J Bassi
Journal:  Front Cell Infect Microbiol       Date:  2018-10-10       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.